Monash University

monash.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

94

Active

33

Phase 3

12

Total enrollment

365,534

Pipeline matrix

Showing 21 of 21 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Atorvastatin 40 Mg Oral—————1
Atorvastatin—————1
Liberal inspired oxygen—————1
Conservative inspired oxygen—————1
Intermediate inspired oxygen—————1
Cefazolin—————1
Water for—————1
Immune Globulin Intravenous—————3
Trimethoprim / Sulfamethoxazole—————2
Trimethoprim Sulfamethoxazole—————1
Amoxycillin/clavulanic acid—————1
Pfizer Bivalent COVID-19 Vaccine—————1
Moderna Bivalent mRNA vaccine—————1
trimethoprim-sulfamethoxazole—————1
amoxycillin/clavulanic acid and ciprofloxacin—————1
Immunoglobulins—————1
Melatonin 10 MG—————1
lidocaine 2% and 10%—————1
Intravenous immunoglobulin—————1
Amoxicillin clavulanic acid—————1
STX-1150—————1

Next readouts

  • 2025-12
  • 2026-06-30
  • 2026-09
  • 2027-03-31
  • 2027-03-31
  • 2027-03-31
  • 2027-03-31
  • 2027-04
  • 2027-04-30
  • 2027-07

Top conditions

  • Heart Failure6
  • Myeloma4
  • Leukemia4
  • Cancer3
  • Non Hodgkin's Lymphoma3
  • Insulin Resistance3
  • Human Papillomavirus Infection2
  • HPV2

Frequently asked questions about Monash University

How many clinical trials does Monash University have on ClinicalTrials.gov?
Monash University is listed as the lead sponsor on 94 clinical trials in ClinicalTrials.gov, 33 of which are currently active (recruiting, enrolling, or ongoing).
How many of Monash University's trials are in Phase 3?
12 of Monash University's trials are in Phase 3, spread across 21 active drug programs.
What therapeutic areas does Monash University focus on?
Monash University's most-studied conditions on ClinicalTrials.gov are Heart Failure, Myeloma, Leukemia, Cancer, Non Hodgkin's Lymphoma.
When are Monash University's next clinical trial readouts?
Monash University has 10 upcoming primary-completion readouts tracked here; the soonest is “A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)”, expected around 2025-12.